Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT1002 Dose Escalation in Acute Coronary Syndrome Undergoing PCI
NCT06533358Phase 2Recruiting
- Sponsor
- Shaanxi Micot Technology Co., Ltd.
- Start
- Feb 2024
- Primary completion
- Dec 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MT1002 in acute coronary syndrome (ACS), sponsored by Shaanxi Micot Technology Co., Ltd. Primary endpoints: Percentage of subjects who achieved target ACT (200-300 s) at Day 30 and Major bleeding events at Day 30. Started Feb 2024; status: recruiting.
02
Drugs
MT1002
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT06533358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06533358.